Epigenetic modifications in breast cancer and their role in personalized medicine.

In cancer, the overall patterns of epigenetic marks are severely distorted from the corresponding normal cell type. It is now well established that these changes can contribute to cancer development through inactivation of tumor suppressor genes and, conversely, through activation of oncogenes. Recent technological advances have enabled epigenome-wide analyses of cancers that are yielding unexpected findings. The study of cancer epigenetics holds great promise for expanding the range of therapeutic opportunities for personalized medicine. Here, we focus on DNA methylation in breast cancer and the potential implications for clinical management of patients.

[1]  J. Jónasson,et al.  Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer , 2006, Breast Cancer Research.

[2]  R. Levine,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[3]  B. Xu,et al.  Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  D. Easton,et al.  Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. , 1995, Oncogene.

[5]  Juri Rappsilber,et al.  JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells , 2010, Nature.

[6]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[7]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[8]  M. Salto‐Tellez,et al.  RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. , 2006, Cancer research.

[9]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[10]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[11]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[12]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[13]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[14]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[15]  V. Bazan,et al.  Breast cancer genome-wide association studies: there is strength in numbers , 2012, Oncogene.

[16]  Johan Staaf,et al.  Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns , 2010, Breast Cancer Research.

[17]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[18]  Manel Esteller,et al.  MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas , 1998, Oncogene.

[19]  R. Kreienberg,et al.  Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  A. Jeyasekharan,et al.  HP1-β mobilization promotes chromatin changes that initiate the DNA damage response , 2008, Nature.

[21]  Meng Li,et al.  Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types , 2011, Human mutation.

[22]  A. Dobrovic,et al.  Methylation of the BRCA1 gene in sporadic breast cancer. , 1997, Cancer research.

[23]  Qiang Yu,et al.  BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A , 2009, Breast Cancer Research.

[24]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[25]  K Miller,et al.  A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Herman,et al.  The Epigenetic promise for prostate cancer diagnosis , 2012, The Prostate.

[27]  M. Esteller,et al.  BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer , 2012, Epigenetics.

[28]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[29]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[30]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[31]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[32]  Yoshiaki Ito,et al.  RUNX3 interactome reveals novel centrosomal targeting of RUNX family of transcription factors , 2012, Cell cycle.

[33]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[34]  J. Thigpen.  Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer , 2011 .

[35]  J. Foekens,et al.  DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and , 2007, European journal of cancer.

[36]  L. Jeng,et al.  Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. , 2011, Cancer research.

[37]  S. Elledge,et al.  A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage , 2010, Proceedings of the National Academy of Sciences.

[38]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[39]  Scott H. Kaufmann,et al.  Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro , 2012, Clinical Cancer Research.

[40]  O. Johannsson,et al.  Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes , 2009, Breast Cancer Research.

[41]  D. Easton,et al.  Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome , 1992, Nature Genetics.

[42]  P. Nederlof,et al.  Genomic signature of BRCA1 deficiency in sporadic basal‐like breast tumors , 2011, Genes, chromosomes & cancer.

[43]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[45]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Charles M Perou,et al.  Systems biology and genomics of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[47]  S. Merajver,et al.  The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. , 2005, Neoplasia.

[48]  A. Godwin,et al.  Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. , 2008, Cancer research.

[49]  Douglas F. Easton,et al.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. , 2012, JAMA.

[50]  Martin Widschwendter,et al.  Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.

[51]  W. Woodward,et al.  EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. , 2011, Cancer cell.

[52]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  E. Citterio,et al.  The emerging role of Polycomb repressors in the response to DNA damage , 2012, Journal of Cell Science.

[54]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[55]  A. Tutt,et al.  Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? , 2012, Breast Cancer Research.

[56]  Pawan Gupta,et al.  Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology , 2010, Molecular Cancer.

[57]  Sean E. Egan,et al.  Elevated PI3K signaling drives multiple Breast Cancer subtypes , 2011, Oncotarget.

[58]  D. Aoki,et al.  Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells , 2012, Oncology reports.

[59]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[60]  J. Herman,et al.  BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[62]  J. Herman,et al.  DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. , 2001, Human molecular genetics.

[63]  A. Feinberg.  Phenotypic plasticity and the epigenetics of human disease , 2007, Nature.

[64]  A. Howell,et al.  Familial breast cancer. , 1994, BMJ.

[65]  A. Tutt,et al.  Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[66]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[67]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Esteller,et al.  CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer , 2011, Epigenetics.

[69]  M. Ringnér,et al.  Molecular and Cellular Pathobiology The Retinoblastoma Gene Undergoes Rearrangements in BRCA 1-De fi cient Basal-like Breast Cancer , 2012 .

[70]  M. Salto‐Tellez,et al.  RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression , 2008, Breast Cancer Research and Treatment.

[71]  S. Taheri,et al.  Methylation status of CpG islands at sites −59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer , 2008, Journal of Genetics.

[72]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[73]  R. Elashoff,et al.  Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment , 2010, Cancer.

[74]  Ming-Ming Zhou,et al.  Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. , 2011, Cancer research.

[75]  D. Sargent,et al.  Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.

[76]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[77]  Tracey M. Filzen,et al.  Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. , 2009, The American journal of pathology.

[78]  P. Nederlof,et al.  High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.

[79]  A. Bird,et al.  Number of CpG islands and genes in human and mouse. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.

[81]  J. Lubiński,et al.  Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer , 2012, Breast Cancer Research.

[82]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[83]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[84]  Thomas Lengauer,et al.  A DNA methylation fingerprint of 1628 human samples. , 2011, Genome research.

[85]  D. Ginzinger,et al.  The ATM gene is a target for epigenetic silencing in locally advanced breast cancer , 2004, Oncogene.

[86]  O. Johannsson,et al.  Correction: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes , 2009, Breast Cancer Research.

[87]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[88]  L. Saal,et al.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.

[89]  K. A. Gelmon.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[90]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[91]  P. Toniolo,et al.  Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. , 2010, Human molecular genetics.

[92]  Zhe Zhang,et al.  Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid , 2006, Clinical Cancer Research.

[93]  T. Aas,et al.  DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response , 2010, Molecular Cancer.

[94]  Y. Drew,et al.  Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. , 2011, Journal of the National Cancer Institute.

[95]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[96]  Alan Ashworth,et al.  Synthetic lethal approaches to breast cancer therapy , 2010, Nature Reviews Clinical Oncology.

[97]  Fang Fang,et al.  Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis , 2011, Science Translational Medicine.

[98]  I. Andrulis,et al.  Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. , 2000, Carcinogenesis.

[99]  S. Furuta,et al.  Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[100]  M. Hoque,et al.  Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  A. D’Andrea,et al.  Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. , 2012, Genes & development.

[102]  M. Stratton,et al.  Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. , 1997, British Journal of Cancer.

[103]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[104]  J. Herman,et al.  Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter , 2007, Oncogene.

[105]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[106]  B. Schuster-Böckler,et al.  Chromatin organization is a major influence on regional mutation rates in human cancer cells , 2012, Nature.

[107]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[108]  T. Sørlie,et al.  Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer , 2010, Breast Cancer Research.

[109]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[110]  Brian J. Stevenson,et al.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. , 2012, Genome research.

[111]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[112]  J. Herman,et al.  Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. , 1998, Cancer research.

[113]  Seung Il Kim,et al.  Personalized Medicine in Breast Cancer: A Systematic Review , 2012, Journal of breast cancer.

[114]  Qinghua Feng,et al.  Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  K. Hess,et al.  Association of BRCA 1 and BRCA 2 Mutations With Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients With Ovarian Cancer , 2011 .

[116]  K. Helin,et al.  DNA methylation: TET proteins—guardians of CpG islands? , 2012, EMBO reports.

[117]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.